Stem cell mobilization and collection in patients with liver cirrhosis

[Guest guest]



Alimentary Pharmacology & Therapeutics

OnlineAccepted Articles (Accepted, unedited articles or abstracts published online for future issues)

To cite this article: S. LORENZINI, A. ISIDORI, L. CATANI, A. GRAMENZI, S. TALARICO, F. BONIFAZI, V. GIUDICE, R. CONTE, M. BACCARANI, M. BERNARDI, S. J. FORBES, R. M. LEMOLI, P. ANDREONE (2008) Stem cell mobilization and collection in patients with liver cirrhosis doi:10.1111/j.1365-2036.2008.03670.x (Online Accepted)

http://www.blackwell-synergy.com/doi/abs/10.1111/j.1365-2036.2008.03670.x

Stem cell mobilization and collection in patients with liver cirrhosis

S. LORENZINI1$1Department of Internal Medicine, Cardioangiology and Hepatology, University of Bologna, Bologna, Italy.$S Lorenzini and A Isidori contributed equally to the manuscript; RM Lemoli and P Andreone share the senior authorship of the study, A. ISIDORI2$2Institute of Haematology and Medical Oncology "L. & A. Seràgnoli", University of Bologna, Bologna, Italy.$S Lorenzini and A Isidori contributed equally to the manuscript; RM Lemoli and P Andreone share the senior authorship of the study, L. CATANI22Institute of Haematology and Medical Oncology "L. & A. Seràgnoli", University of Bologna, Bologna, Italy., A. GRAMENZI11Department of Internal Medicine, Cardioangiology and Hepatology, University of Bologna, Bologna, Italy., S. TALARICO22Institute of Haematology and Medical Oncology "L. & A. Seràgnoli", University of Bologna, Bologna, Italy., F. BONIFAZI22Institute of Haematology and Medical Oncology "L. & A. Seràgnoli", University of Bologna, Bologna, Italy., V. GIUDICE33Immuno-Haematology Service and Blood Bank, Malpighi-S.Orsola Hospital, Bologna, Italy., R. CONTE33Immuno-Haematology Service and Blood Bank, Malpighi-S.Orsola Hospital, Bologna, Italy., M. BACCARANI22Institute of Haematology and Medical Oncology "L. & A. Seràgnoli", University of Bologna, Bologna, Italy., M. BERNARDI11Department of Internal Medicine, Cardioangiology and Hepatology, University of Bologna, Bologna, Italy., S. J. FORBES44 MRC/Centre for Inflammation Research, The Queen’s Medical Research Institute, University of Edinburgh, Edinburgh, UK., R. M. LEMOLI2$2Institute of Haematology and Medical Oncology "L. & A. Seràgnoli", University of Bologna, Bologna, Italy.$S Lorenzini and A Isidori contributed equally to the manuscript; RM Lemoli and P Andreone share the senior authorship of the study & P. ANDREONE1$1Department of Internal Medicine, Cardioangiology and Hepatology, University of Bologna, Bologna, Italy.$S Lorenzini and A Isidori contributed equally to the manuscript; RM Lemoli and P Andreone share the senior authorship of the study.

1Department of Internal Medicine, Cardioangiology and Hepatology, University of Bologna, Bologna, Italy. 2Institute of Haematology and Medical Oncology "L. & A. Seràgnoli", University of Bologna, Bologna, Italy. 3Immuno-Haematology Service and Blood Bank, Malpighi-S.Orsola Hospital, Bologna, Italy. 4 MRC/Centre for Inflammation Research, The Queen’s Medical Research Institute, University of Edinburgh, Edinburgh, UK.

Corresponding Author: Prof. Pietro Andreone,Department of Internal Medicine, Cardioangiology and Hepatology, University of Bologna, Italy.Via Massarenti 9, 40138. 40100 Bologna, ITALYPhone:+390516363618;e-mail: pietro.andreone@...

$S Lorenzini and A Isidori contributed equally to the manuscript; RM Lemoli and P Andreone share the senior authorship of the study

ABSTRACT

Background: Bone marrow derived stem cells (BMSC) and granulocyte colony-stimulating factor (G-CSF) have been proved to contribute to tissue regeneration after liver injury.

Patients and Methods: In this study, we treated 18 patients affected by liver cirrhosis with increasing doses of G-CSF to mobilize CD34+ and CD133+ BMSC into the peripheral blood.

Results: The dose finding phase demonstrated that 15 μg/Kg/day of G-CSF is the optimal dose to mobilize both CD34+ and CD133+ stem cells. Circulating BMSC were collected by a single step leukapheresis in 3 patients and the mean number of CD34+ and CD133+ cells cryopreserved was 1.3±0.7 and 1.2±0.5 x106/kg, respectively. No severe adverse events were observed during the drug administration and SC collection. Noteworthy, none of the patients showed a significant modification of liver function.

Conclusions: Our study demonstrates that G-CSF administration and BMSC collection from the peripheral blood is possible and safe in patients with liver cirrhosis. The optimal dose to mobilize BMSC in cirrhotics is 15 μg/Kg/day. At this dose, G-CSF does not seem to modify the residual liver function in cirrhotic patients.